



(12) Translation of
European patent specification

(11) NO/EP 3494972 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 31/513 (2006.01)

A61K 45/06 (2006.01)

A61P 31/18 (2006.01)

A61K 9/00 (2006.01)

A61P 31/00 (2006.01)

A61P 37/04 (2006.01)

A61K 31/5365 (2006.01)

A61P 31/12 (2006.01)

A61P 43/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.04.08
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.12.13
(86)	European Application Nr.	19151897.6
(86)	European Filing Date	2011.01.24
(87)	The European Application's Publication Date	2019.06.12
(30)	Priority	2010.01.27, US, 29858910 P
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
	Designated Extension States:	BA; ME
(73)	Proprietor	VIIV Healthcare Company, 251 Little Falls Drive, Wilmington, DE 19808, USA
(72)	Inventor	UNDERWOOD, Mark Richard, c/o GlaxoSmithKline, Global Patents Dept Five Moore Drive Research Triangle Park, NC North Carolina 27709, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54)	Title	COMBINATIONS OF DOLUTEGRAVIR AND LAMIVUDINE FOR THE TREATMENT OF HIV INFECTION
(56)	References Cited:	Anonymous: "A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects - Full Text View - ClinicalTrials.gov", NCT00951015, 3 August 2009 (2009-08-03), XP055582403, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/NC T00951015 [retrieved on 2019-04-18] BEALE K K ET AL: "COMBINATIONS OF REVERSE TRANSCRIPTASE, PROTEASE, AND INTEGRASE INHIBITORS CAN BE SYNERGISTIC IN VITRO AGAINST DRUG-SENSITIVE AND RT INHIBITOR-RESISTANT MOLECULAR CLONES OF HIV-1", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 46, no. 3, 1 June 2000 (2000-06-01), pages 223-232, XP001027294, ISSN: 0166-3542, DOI: 10.1016/S0166-3542(00)00083-8 J. LALEZARI ET AL: "Shionogi-GlaxoSmithKline Pharmaceuticals, LLC Potent Antiviral Activity of S/GSK1349572, A Next Generation Integrase Inhibitor (INI), in INI-Na?ve HIV-1-Infected Patients: ING111521 Protocol", 5IAS 2009 - 5TH CONFERENCE ON HIV PATHOGENESIS, TREATMENT AND PREVENTION, 19 July 2009 (2009-07-19), pages 1-15, XP055280561, Cape Town South Africa A SATO ET AL: "S/GSK1349572 is a potent next-generation HIV integrase inhibitor", HIV MEDICINE, vol. 10, no. Suppl. 2, 19 October 2009 (2009-10-19), pages 92-92, XP055582260, GB ISSN: 1464-2662, DOI: 10.1111/j.1468-1293.2009.00792.x DATABASE Chemical Abstracts Regist [Online] Chemical Abstracts Service; 22 September 2008 (2008-09-22), Anon.: "Dolutegravir", Database accession no. 1051375-16-6

GALIZZI NADIA ET AL: "Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, ELSEVIER, AMSTERDAM, NL, vol. 55, no. 3, 9 January 2020 (2020-01-09), ISSN: 0924-8579, DOI: 10.1016/J.IJANTIMICAG.2020.105893 [retrieved on 2020-01-09]

LASKEY SARAH B. ET AL: "Quantitative evaluation of the antiretroviral efficacy of dolutegravir", JCI INSIGHT, vol. 1, no. 19, 17 November 2016 (2016-11-17), DOI: 10.1172/jci.insight.90033

CAHN PEDRO ET AL: "Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials", THE LANCET, vol. 393, 9 November 2018 (2018-11-09), pages 143-155, DOI: dx.doi.org/10.1016/ S0140-6736(18)32462-0


VAN WYK JEAN ET AL: "Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study", CLINICAL INFECTIOUS DISEASES, vol. 71, no. 8, 6 January 2020 (2020-01-06), pages 1920-1929, US ISSN: 1058-4838, DOI: 10.1093/cid/ciz1243

J ROCKSTROH ET AL: "Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276)", JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, vol. 13, 8 November 2010 (2010-11-08), pages O50-O50, XP055582245, London, UK ISSN: 1758-2652, DOI: 10.1186/1758-2652-13-S4-O50

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Kombinasjon omfattende en forbindelse med formel (I)



- 5 eller et farmasøytisk akseptabelt salt derav, og lamivudin.

2. Kombinasjon ifølge 1 hvor det farmasøytisk akseptable saltet av en forbindelse med formel (I) er natriumsaltet.

- 10 3. Kombinasjon ifølge krav 1 for bruk ved medisinsk terapi.

4. Kombinasjon ifølge krav 1 for bruk ved behandling av HIV-infeksjon.

- 15 5. Farmasøytisk sammensetning omfattende en kombinasjon ifølge krav 1 sammen med en farmasøytisk akseptabel bærer for denne.

6. Kombinasjon for bruk ifølge krav 4 hvor kombinasjonen blir administrert samtidig.

7. Kombinasjon for bruk ifølge krav 4 hvor kombinasjonen blir administrert sekvensielt.

20

8. Bruk av en kombinasjon ifølge krav 1 for fremstilling av et medikament for behandling av HIV-infeksjon.